Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Quantum Biopharma Ltd. (QNTM:NASDAQ), powered by AI.
Quantum Biopharma Ltd. is currently trading at $3.64. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Quantum Biopharma Ltd. on Alpha Lenz.
Quantum Biopharma Ltd.'s P/E ratio is -0.5.
“Quantum Biopharma Ltd. trades at a P/E of -0.5 (undervalued) with modest ROE of -284.4%.”
Ask for details →Quantum Biopharma Ltd. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative therapies. Its primary function is to harness cutting-edge biotechnology to address unmet medical needs in various critical areas. Quantum Biopharma engages in extensive research and development to discover novel drug candidates, utilizing advanced technologies such as genetic engineering and precision medicine. The company focuses on therapeutic fields including oncology, neurology, and rare genetic disorders, significantly impacting the healthcare and pharmaceutical sectors. With a commitment to improving patient outcomes, Quantum Biopharma collaborates with academic institutions and strategic partners to enhance its drug development pipeline. As a key player in the biopharmaceutical market, Quantum Biopharma holds a pivotal role in driving forward medical innovation and expanding the availability of life-saving treatments. By advancing its product portfolio through rigorous clinical trials and regulatory approvals, Quantum Biopharma continues to contribute to the global healthcare landscape, addressing complex health challenges and promoting wellness.
“Quantum Biopharma Ltd. trades at a P/E of -0.5 (undervalued) with modest ROE of -284.4%.”
Ask for details →Quantum Biopharma Ltd. (ticker: QNTM) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 17 employees. Market cap is $12M.
The current price is $3.64 with a P/E ratio of -0.46x and P/B of 1.73x.
ROE is -284.44%.